David Cho

David Cho

Auto-generated profile, based on publicly available information

David Cho

Mayo Clinic Alix School of Medicine, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2025 in Regional Anesthesia & Pain Medicine
Verified
Journal Article
Open access
PDF file
RDRyan Steven D’Souza
Ryan Steven D’Souza
YHYeng F Her
Yeng F Her
MMMahmoud Morsi
Mahmoud Morsi
HSHunter Soleymani
Hunter Soleymani
DBDylan Banks
Dylan Banks
NHNasir Hussain
Nasir Hussain
Background: Peripheral nerve stimulation (PNS) has emerged as a promising neurostimulation modality, yet its effectiveness and durability for chronic pain remain uncertain. We conducted a systematic review and meta-analysis to evaluate changes in pain intensity following implantable PNS therapy. Methods: Eligible studies included adults (≥18 years) with chronic pain treated with an implantable PNS system, and pain intensity was assessed at baseline and follow-up time points. The primary outcome was change in pain intensity from baseline to 6 months after PNS implantation. Secondary outcomes included changes in pain intensity at 3, 12 and 24 months after PNS implantation. Standardized mean differences (Hedges’ g ) were pooled using a random-effects model. Results: A total of 106 studies comprising 9272 patients were included. PNS was associated with large, statistically significant reductions in pain intensity from baseline to all time points: 3 months (Hedges’ g 2.92; 95% CI 2.62 to 3.21), 6 months (Hedges’ g 3.08; 95% CI 2.68 to 3.48), 12 months (Hedges’ g 2.68; 95% CI 2.30 to 3.05) and 24 months (Hedges’ g 2.08; 95% CI 1.68 to 2.48) (all p<0.001). However, the certainty of evidence as assessed by the Grading of Recommendations Assessment, Development and Evaluation criteria was rated as low for the primary outcome, due to pooling from observational studies, risk of bias, and heterogeneity (statistical, clinical and methodological). Subgroup analyses revealed no differences by study design or device type, while smaller effect sizes were reported in industry-funded studies and those with declared conflicts of interest. The largest effect sizes were observed in pelvic and upper extremity pain, whereas the smallest in truncal pain. Conclusion: Implantable PNS provides persistent and clinically meaningful analgesia for chronic pain, with benefits sustained up to 24 months. These findings support broader clinical adoption and provide evidence to inform pay0r coverage and policy decisions.

30 January 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
TPTana S Pottorf
Tana S Pottorf
MFMicaella P. Fagan
Micaella P. Fagan
BBBryan F. Burkey
Bryan F. Burkey
DCDavid J. Cho
David J. Cho
JVJames E. Vath
James E. Vath
PTPamela Tran
Pamela Tran
The ciliopathies Bardet-Biedl syndrome and Alström syndrome are genetically inherited pleiotropic disorders with hyperphagia and obesity as primary clinical features. Methionine aminopeptidase 2 inhibitors (MetAP2i) have been shown in preclinical and clinical studies to reduce food intake, body weight, and adiposity. Here, we investigated the effects of MetAP2i administration in a mouse model of ciliopathy produced by conditional deletion of the Thm1 gene in adulthood. Thm1 conditional knockout (cko) mice showed decreased hypothalamic proopiomelanocortin expression as well as hyperphagia, obesity, metabolic disease, and hepatic steatosis. In obese Thm1 -cko mice, 2-week administration of MetAP2i reduced daily food intake and reduced body weight 17.1% from baseline (vs. 5% reduction for vehicle). This was accompanied by decreased levels of blood glucose, insulin, and leptin. Further, MetAP2i reduced gonadal adipose depots and adipocyte size and improved liver morphology. This is the first report to our knowledge of MetAP2i reducing hyperphagia and body weight and ameliorating metabolic indices in a mouse model of ciliopathy. These results support further investigation of MetAP2 inhibition as a potential therapeutic strategy for ciliary-mediated forms of obesity.

24 October 2024 in Transfusion
Verified
Journal Article
Closed access
DCDavid J. Cho
David J. Cho
AKAllan M. Klompas
Allan M. Klompas
JGJessica A. Gonzalez
Jessica A. Gonzalez
JPJamie L. Petsch
Jamie L. Petsch
JBJen M. Burt
Jen M. Burt
MWMatthew A. Warner
Matthew A. Warner

12 April 2022 in Face
Verified
Journal Article
Closed access
TRTulsi Roy
Tulsi Roy
JCJulia Chavez
Julia Chavez
DCDavid Cho
David Cho
RSRafal Sobota
Rafal Sobota
RRRussell R. Reid
Russell R. Reid
Purpose: Within open cranial vault reconstruction (CVR) for craniosynostosis, efforts have been directed at minimizing the bicoronal scar, which contributes to increased patient stigmatization and decreased parental satisfaction. To understand these esthetic considerations across multiple centers, we evaluated demographic and clinical determinants of patient scar self-consciousness, parental scar satisfaction, and parental satisfaction with their children’s overall medical and surgical care. Methods: A 25-item questionnaire was distributed within an 18 500-member craniosynostosis parental online support group. Parents were asked to grade patient scar self-consciousness, parental scar satisfaction, and parental satisfaction with their children’s overall care on a 10-point Likert scale. A t-test and linear regression were performed for binary and continuous variables. Results: Of 838 responses, 516 met inclusion criteria. 32% of patients had visible scar alopecia and 25% of respondents reported their child’s hair is deliberately styled to disguise the scar. 2% of patients underwent scar revision. Older age, complications, ongoing symptoms, and increased number of surgeries were negatively associated with parental scar satisfaction, patient self-consciousness, and parental satisfaction with overall management. Ethnicity and hair texture were not associated with patient self-consciousness or parental satisfaction with care. Incision type (zig-zag/wavy compared to straight bicoronal incisions) showed no significant difference in subjective outcomes measures or rates of external stigmatizing behavior between the 2 groups. Conclusions: Bicoronal scarring has complex and multifaceted psychosocial effects. Advanced age, complications, ongoing symptoms, and increased number of surgeries are key determinants of patient and parent satisfaction, though parental esthetic satisfaction may be more sensitive to external stigmatizing behavior. This study calls for a reappraisal of conventional teaching regarding the impact of incision design. While craniofacial morphology, neurological development, and social functioning may be more foundational to overall patient and parent satisfaction, the esthetic value of the bicoronal scar should not be undervalued.

17 November 2025 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
DCDavid Cho
David Cho
TWToby N. Weingarten
Toby N. Weingarten
JSJuraj Sprung
Juraj Sprung
AZAurelia Zodl
Aurelia Zodl
MRMartin J. Ryll
Martin J. Ryll
THTracy E. Harrison
Tracy E. Harrison
Dantrolene is the definitive treatment for malignant hyperthermia (MH), a rare and life-threatening disorder. This retrospective study aimed to achieve two objectives: (1) to characterize the indications and frequency of dantrolene administration in both medical and surgical settings, and (2) to evaluate whether perioperative dantrolene may serve as a surrogate marker for identifying MH cases. Using pharmacy records, we identified hospitalized patients who received dantrolene between 2010 and 2024. Each recipient underwent a chart review to examine the clinical context of dantrolene administration. A total of 1,199,450 inpatient pharmacy records were reviewed, revealing 118 patients who received dantrolene, resulting in an incidence rate of 1 in 10,165 hospital admissions (95% CI: 1 in 8,488 to 1 in 12,280). Among these, 87 patients (74%) received oral dantrolene: 84 for chronic spasticity, two for neuroleptic malignant syndrome, and one as preoperative prophylaxis due to a history of MH. The remaining 31 patients (26%) received intravenous dantrolene. Seventeen patients received perioperative dantrolene for suspected MH; of these, nine cases (53%) were subsequently clinically confirmed as MH. Based on these findings and the total number of surgical procedures involving general anesthesia (n=885,127), the estimated prevalence of MH following general anesthesia was calculated to be 1 in 98,328 exposures (95% CI: 1 in 51,813 to 1 in 215,054). Dantrolene was administered at an approximate rate of 1 per 10,000 hospital admissions, primarily in oral formulation for chronic spasticity. Among the patients who received perioperative dantrolene, approximately half were confirmed to have MH, resulting in an estimated MH prevalence of 1 in 100,000 patients exposed to general anesthesia.